Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT SC versus IV efgartigimod in generalized myasthenia gravis
NL-OMON51130Phase 3Active, not recruiting
- Sponsor
- argenx
- Start
- Jun 2021
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in myasthenia gravis (MG) comparing Efgartigimod PH20 SC with Efgartigimod IV (2 arms). Primary endpoint: Percent reduction from baseline in total IgG levels at Day 29. Started Jun 2021; status: active, not recruiting.
02
Drugs
efgartigimod alfaENHANZE
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NL-OMON51130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51130.